9 September 2024 September 2024 decisions news release SMC advice on four new medicines The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, July 8) published advice on four medicines.
24 July 2024 SMC publishes Collaborative Advice Documents for ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis.
8 July 2024 July 2024 decisions news release SMC advice on eight new medicines The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, July 8) published advice on eight medicines.
20 June 2024 NICE issues final draft guidance on multiple technology appraisal (MTA), ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor– ivacaftor for treating cystic fibrosis. NICE issues final draft guidance on multiple technology appraisal (MTA), ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor– ivacaftor for treating cystic fibrosis.
10 June 2024 June 2024 decisions news release SMC advice on six new medicines The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, June 10) published advice on six medicines.
13 May 2024 May 2024 decisions news release SMC advice on two new medicines The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, May 13) published advice on two medicines.
8 May 2024 SMC publishes Collaborative Advice Documents for remdesivir and tixagevimab plus cilgavimab for COVID-19
9 April 2024 NICE issues final draft guidance for use of remdesivir and also for tixagevimab-cilgavimab (Evusheld®) for treatment of COVID-19 Final draft guidance for remdesivir and for tixagevimab-cilgavimab has been published by the National Institute for Health and Care Excellence (NICE).
